|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 10,047,117: Scope, Claims, and Landscape
Executive Summary
United States Patent 10,047,117, granted on August 14, 2018, to Bristol-Myers Squibb Company, covers methods of treating various cancers, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and melanoma, by administering nivolumab. Nivolumab is a programmed cell death protein 1 (PD-1) blocking antibody. The patent's claims define specific dosing regimens and combinations with other therapeutic agents, aiming to enhance treatment efficacy. The patent landscape surrounding nivolumab and PD-1 inhibitors is highly competitive, with numerous active patents and ongoing litigation, particularly concerning combination therapies and methods of use. This analysis details the patent's core claims, its scope in relation to cancer treatment, and its position within the broader competitive intellectual property environment.
What Is the Core Technology Protected by Patent 10,047,117?
Patent 10,047,117 protects methods of treating specific types of cancer. The therapeutic agent is nivolumab, an antibody that targets the PD-1 receptor. The patent focuses on specific treatment protocols, including dosage, frequency, and combination therapies designed to improve patient outcomes in certain malignancies.
- Therapeutic Agent: Nivolumab (Opdivo®)
- Mechanism of Action: PD-1 blocking antibody
- Target Diseases: Hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), melanoma. The patent also references other cancers such as renal cell carcinoma (RCC) and colorectal cancer (CRC) in its broader context but specifically claims methods for the aforementioned three.
- Key Innovation: Specific methods of administration and combination therapy regimens aimed at enhancing anti-tumor response and patient survival.
What Are the Key Claims in Patent 10,047,117?
The patent's claims are structured to protect specific methods of medical treatment. Claim 1, the independent method claim, is central to the patent's scope. Dependent claims further refine these methods by specifying dosages and combination partners.
-
Claim 1: A method of treating a subject diagnosed with hepatocellular carcinoma (HCC), comprising administering to the subject an effective amount of an anti-PD-1 antibody that binds to a PD-1 receptor, wherein the anti-PD-1 antibody is nivolumab. The method also specifies a dosage of 3 mg/kg every two weeks.
- This claim broadly covers the use of nivolumab for HCC treatment at a defined dosage.
-
Claim 2: A method of treating a subject diagnosed with non-small cell lung cancer (NSCLC), comprising administering to the subject an effective amount of nivolumab, wherein the anti-PD-1 antibody is nivolumab, and wherein the method comprises administering nivolumab at a dosage of 3 mg/kg every two weeks.
- This claim specifically addresses NSCLC treatment with nivolumab at the same 3 mg/kg every two-week regimen.
-
Claim 3: A method of treating a subject diagnosed with melanoma, comprising administering to the subject an effective amount of nivolumab, wherein the anti-PD-1 antibody is nivolumab, and wherein the method comprises administering nivolumab at a dosage of 3 mg/kg every two weeks.
- This claim targets melanoma treatment with nivolumab, utilizing the same dosing parameters.
-
Claim 4: The method of claim 1, wherein the effective amount of nivolumab is administered intravenously.
- Specifies the route of administration.
-
Claim 5: The method of claim 1, wherein the effective amount of nivolumab is administered from 2 to 4 mg/kg.
- Broadens the dosage range slightly beyond the specific 3 mg/kg in claim 1.
-
Claim 6: The method of claim 1, wherein the effective amount of nivolumab is administered every two weeks.
- Confirms the frequency of administration.
-
Claim 7: The method of claim 1, further comprising administering at least one additional therapeutic agent.
- This is a critical dependent claim enabling combination therapy.
-
Claim 8: The method of claim 7, wherein the at least one additional therapeutic agent is selected from the group consisting of ipilimumab, chemotherapy, and radiation therapy.
- Provides specific examples of combination agents, notably including ipilimumab, another immune checkpoint inhibitor.
The claims' scope is defined by the specific cancer type, the antibody (nivolumab), the dosage (3 mg/kg every two weeks, with a broader range in Claim 5), and the potential inclusion of combination therapies.
What Is the Scope of Protection for Patent 10,047,117?
The patent's scope is primarily directed at the method of treatment. This means it protects the act of administering nivolumab under the specified conditions for treating HCC, NSCLC, and melanoma. It does not inherently protect the composition of matter of nivolumab itself, which is likely covered by separate composition of matter patents.
- Geographic Scope: United States.
- Therapeutic Scope:
- Hepatocellular Carcinoma (HCC)
- Non-Small Cell Lung Cancer (NSCLC)
- Melanoma
- Dosage and Administration Scope:
- Specific dosage: 3 mg/kg every two weeks.
- Broader dosage range: 2 to 4 mg/kg every two weeks.
- Route of administration: Intravenous.
- Combination Therapy Scope: Includes administration of nivolumab alongside ipilimumab, chemotherapy, or radiation therapy.
This scope allows Bristol-Myers Squibb to assert its patent rights against entities that practice these specific methods of treatment without authorization. The method of treatment patent is particularly relevant in the context of generic drug entry, as it can create barriers even if the underlying drug substance is off-patent.
How Does Patent 10,047,117 Fit into the Broader Patent Landscape for PD-1 Inhibitors?
The intellectual property landscape for PD-1 inhibitors, including nivolumab, is densely populated and highly competitive. Numerous patents exist for the antibody itself, its manufacturing, formulations, and various methods of use in treating different cancers. Patent 10,047,117 contributes to this landscape by securing specific therapeutic regimens.
- Key Players: Bristol-Myers Squibb (BMS), Merck & Co. (Keytruda®), Regeneron Pharmaceuticals, and others hold significant patent portfolios.
- Types of Patents:
- Composition of Matter: Patents claiming the antibody molecule itself. These are often the earliest and strongest patents.
- Method of Use: Patents claiming the use of the antibody to treat specific diseases or in specific patient populations. Patent 10,047,117 falls under this category.
- Formulation Patents: Patents protecting specific drug formulations (e.g., stable liquid formulations).
- Manufacturing Patents: Patents covering processes for producing the antibody.
- Competitive Dynamics:
- Patent Thicketing: Companies file numerous patents to create a broad protective barrier around their products.
- Litigation: The field is subject to significant patent litigation, particularly concerning infringement of method of use claims and challenges to patent validity. Companies often sue to prevent market entry of biosimilars or competing therapies.
- Exclusivity Periods: Patents provide market exclusivity, allowing companies to recoup R&D investments. Method of use patents can extend exclusivity beyond the expiration of core composition of matter patents.
- Patent 10,047,117's Position: This patent complements BMS's broader intellectual property strategy for nivolumab. It specifically targets established dosing regimens and combination therapies that are clinically relevant and contribute to the drug's commercial success. Its validity and enforceability are crucial for maintaining market exclusivity for these specific treatment methods.
What Are Potential Challenges or Litigation Risks Associated with Patent 10,047,117?
As with any drug patent, especially those covering methods of treatment in a competitive market, Patent 10,047,117 faces potential challenges and litigation risks.
- Invalidity Challenges: Competitors may seek to invalidate the patent by arguing that the claimed methods were obvious or not novel at the time of filing. This can involve citing prior art, including scientific publications, earlier patents, or clinical trial data that predates the priority date of the patent.
- Infringement Litigation: Companies developing or marketing biosimilar nivolumab or alternative PD-1 inhibitors may be accused of infringing this patent. Litigation would typically focus on whether their proposed treatments fall within the scope of claims 1-8.
- Claim Construction Disputes: The interpretation of patent claims (claim construction) is often a significant point of contention in patent litigation. Courts will determine the precise meaning of terms like "effective amount," "subject diagnosed with," and the specific dosages and combinations.
- Prior Art: The existence of earlier patents or publications detailing similar dosing or combination strategies for PD-1 inhibitors could be used to argue that the invention claimed in 10,047,117 was already known and thus unpatentable. For example, if prior art discussed the use of nivolumab at 3 mg/kg for NSCLC, it could weaken the patentability of claim 2.
- Biosimilar Pathway: For biosimilar developers, navigating method of use patents is a critical step. They must design their biosimilar products and proposed labeling to avoid direct infringement of such patents, often by seeking alternative indications or dosing regimens not covered by the patent.
What Is the Commercial Significance of Patent 10,047,117?
The commercial significance of Patent 10,047,117 lies in its ability to protect specific, clinically validated treatment regimens for high-value cancer indications. Nivolumab (Opdivo®) is a blockbuster drug, and its revenue stream is substantial. Method of use patents like this one are crucial for extending market exclusivity and defending against generic competition, particularly for specific indications and dosing strategies.
- Market Exclusivity: This patent helps maintain BMS's exclusive right to market nivolumab for HCC, NSCLC, and melanoma using the specified 3 mg/kg every two weeks dosage, and in combination with ipilimumab, chemotherapy, or radiation therapy.
- Revenue Protection: By preventing competitors from using these specific, effective treatment methods, the patent safeguards significant revenue generated by Opdivo®.
- Strategic Importance in Combination Therapies: Claim 7 and 8, which cover combination therapies, are particularly important. Combination treatments often show improved efficacy and can become standard of care, making protection of these specific combinations highly valuable. For instance, the combination of nivolumab and ipilimumab has been a significant part of BMS's strategy.
- Defense Against Biosimilars: As patents on the composition of matter for antibodies expire or are challenged, method of use patents become a primary tool for defending market share against biosimilar entrants. A biosimilar developer may be able to obtain approval for a nivolumab biosimilar, but they might be blocked from marketing it for indications or using regimens covered by this patent.
- Dosing Optimization: The patent protects specific dosing regimens that have been proven effective in clinical trials. These specific regimens are what physicians are trained to use and what regulators approve.
The patent's commercial value is directly tied to the clinical success and market penetration of nivolumab in the protected cancer indications.
Key Takeaways
- Patent 10,047,117 specifically protects methods of treating hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and melanoma using nivolumab at a dosage of 3 mg/kg every two weeks.
- The patent also covers combination therapies involving nivolumab with ipilimumab, chemotherapy, or radiation.
- This patent is a method of use patent, complementing broader intellectual property protection for nivolumab by safeguarding specific therapeutic regimens.
- The PD-1 inhibitor landscape is highly competitive, with numerous patents and ongoing litigation, making this patent a potential target for challenges or a tool in enforcement actions.
- Commercially, Patent 10,047,117 is significant for protecting revenue streams from Opdivo® by extending market exclusivity for established and effective treatment protocols.
Frequently Asked Questions
- Does Patent 10,047,117 cover nivolumab as a drug substance itself?
No, Patent 10,047,117 is a method of use patent. It protects the specific ways the drug is administered to treat certain cancers, not the chemical composition of nivolumab itself.
- Can another company sell nivolumab if this patent is still in force?
Another company may sell nivolumab if they have a license from Bristol-Myers Squibb or if their intended use does not infringe on the patent's claims, for example, by targeting different cancer types or using different dosing regimens not protected by the patent.
- What is the significance of the combination therapy claims?
Claims related to combination therapy (e.g., with ipilimumab) are critical as these regimens often offer enhanced efficacy and can represent significant portions of a drug's market share and clinical utility.
- How long will this patent provide protection?
The patent was granted on August 14, 2018. United States utility patents generally have a term of 20 years from the filing date. However, patent term adjustments or extensions (e.g., for regulatory delays) can alter the effective expiration date.
- Can a biosimilar company challenge the validity of this patent?
Yes, a biosimilar developer can challenge the validity of method of use patents, for instance, by arguing the claims are obvious based on prior art, or not novel, as part of their strategy to enter the market.
Citations
[1] Bristol-Myers Squibb Company. (2018). Method of treating cancer. U.S. Patent No. 10,047,117. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
